AstraZeneca is a company that makes bio-carrier solution for humanized antibody that has been used in the drug delivery process in human physiological system. The manager is considering adding a nonmetal-based nanoparticle (Type C or Si) to its solution to increase the product performance at medium temperatures. The costs associated with each type are estimated. If the company's MARR is 15% per year, Then: a) Draw cash flow diagram for cost estimates for Type C and Type Si b) What is the LCM c) Using LCM and study period of 6 years determine the present worth of the two types (C & Si), d) Which nanoparticle type should the company select for each method (LCM and Study Period)? Give reasons for your choice